NO20031540L - Benzamidforbindelser som Apo-B-sekresjonsinhibitorer - Google Patents

Benzamidforbindelser som Apo-B-sekresjonsinhibitorer

Info

Publication number
NO20031540L
NO20031540L NO20031540A NO20031540A NO20031540L NO 20031540 L NO20031540 L NO 20031540L NO 20031540 A NO20031540 A NO 20031540A NO 20031540 A NO20031540 A NO 20031540A NO 20031540 L NO20031540 L NO 20031540L
Authority
NO
Norway
Prior art keywords
apo
benzamide compounds
secretion inhibitors
secretion
inhibitors
Prior art date
Application number
NO20031540A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031540D0 (no
Inventor
Hisashi Takasugi
Takeshi Terasawa
Yoshikazu Inoue
Hideko Nakamura
Akira Nagayoshi
Hiroaki Ohtake
Yoshiro Furukawa
Masafumi Mikami
Kazumasa Hinoue
Makoto Ohtsubo
Original Assignee
Daiso Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR0583A external-priority patent/AUPR058300A0/en
Priority claimed from AUPR6666A external-priority patent/AUPR666601A0/en
Application filed by Daiso Co Ltd filed Critical Daiso Co Ltd
Publication of NO20031540D0 publication Critical patent/NO20031540D0/no
Publication of NO20031540L publication Critical patent/NO20031540L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20031540A 2000-10-05 2003-04-04 Benzamidforbindelser som Apo-B-sekresjonsinhibitorer NO20031540L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR0583A AUPR058300A0 (en) 2000-10-05 2000-10-05 Benzamide compounds
AUPR6666A AUPR666601A0 (en) 2001-07-27 2001-07-27 Benzamide compounds
PCT/JP2001/008581 WO2002028835A1 (en) 2000-10-05 2001-09-28 Benzamide compounds as apo b secretion inhibitors

Publications (2)

Publication Number Publication Date
NO20031540D0 NO20031540D0 (no) 2003-04-04
NO20031540L true NO20031540L (no) 2003-06-05

Family

ID=25646463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031540A NO20031540L (no) 2000-10-05 2003-04-04 Benzamidforbindelser som Apo-B-sekresjonsinhibitorer

Country Status (16)

Country Link
US (1) US20040058903A1 (xx)
EP (1) EP1326835A1 (xx)
JP (1) JP2004510763A (xx)
KR (1) KR20030067675A (xx)
CN (1) CN1478077A (xx)
BR (1) BR0114657A (xx)
CA (1) CA2425097A1 (xx)
CZ (1) CZ20031230A3 (xx)
HU (1) HUP0301249A2 (xx)
IL (1) IL155196A0 (xx)
MX (1) MXPA03003002A (xx)
NO (1) NO20031540L (xx)
NZ (1) NZ525591A (xx)
PL (1) PL362546A1 (xx)
RU (1) RU2003112691A (xx)
WO (1) WO2002028835A1 (xx)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002098839A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides et procede de preparation de ceux-ci
CA2460682C (en) 2002-02-28 2010-11-30 Japan Tobacco Inc. Ester compound and medical use thereof
AU2003252715B2 (en) * 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
FR2846327B1 (fr) * 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
CA2505604A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
EP1608365B1 (en) * 2003-03-31 2013-10-02 R-Tech Ueno, Ltd. Method for treating vascular hyperpermeable disease
EP1669345A4 (en) * 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
EA010369B1 (ru) 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
FR2866889B1 (fr) * 2004-02-27 2006-06-02 Oreal Para-phenylenediamine secondaire n-alkylheteroarylee, composition tinctoriale comprenant une telle para-phenylenediamine, procede mettant oeuvre cette composition et utilisation
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7683097B2 (en) * 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
FR2871463B1 (fr) * 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
JP5060133B2 (ja) * 2004-10-18 2012-10-31 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
EP1803452A4 (en) * 2004-10-18 2009-12-23 Japan Tobacco Inc ESTER DERIVATIVE AND ITS PHARMACEUTICAL USE THEREOF
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
EP2314295B1 (en) 2005-07-29 2015-01-28 Resverlogix, Inc Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP1951053A4 (en) * 2005-10-19 2010-12-01 Merck Sharp & Dohme CETP INHIBITORS
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
RS55192B1 (sr) * 2005-11-24 2017-01-31 Dompé Farm S P A Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže
CN101489558A (zh) * 2006-05-08 2009-07-22 阿里亚德医药股份有限公司 炔类杂芳基化合物
US8461167B2 (en) 2006-05-08 2013-06-11 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US8278307B2 (en) * 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
EP2118074B1 (en) 2007-02-01 2014-01-22 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
CN101633638B (zh) * 2008-06-20 2012-07-25 江苏国华投资有限公司 一类组蛋白去乙酰化酶抑制剂及其应用
PL2346837T3 (pl) 2008-06-26 2015-07-31 Resverlogix Corp Sposoby wytwarzania pochodnych chinazolinonu
MX2011000839A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
CN102131809A (zh) 2008-07-23 2011-07-20 沃泰克斯药物股份有限公司 三环吡唑并吡啶激酶抑制剂
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2313372B1 (en) 2008-08-06 2013-04-10 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
MX337352B (es) 2009-03-18 2016-02-29 Resverlogix Corp Nuevos agentes anti-inflamatorios.
EP3431086B1 (en) 2009-04-22 2020-06-17 Resverlogix Corp. Novel anti-inflammatory agents
JP5627675B2 (ja) 2009-05-06 2014-11-19 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジン
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
AU2011209726A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
AU2011209651A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
EP2571860A1 (en) * 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
EP2583965B1 (en) 2010-07-15 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic ring compound
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
US20140335019A1 (en) * 2011-12-02 2014-11-13 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
KR20200115607A (ko) 2018-01-31 2020-10-07 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN110734387B (zh) * 2018-07-20 2021-02-12 中国科学院福建物质结构研究所 轴手性联苯环-链异构化合物及其制备方法与应用
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
YU23499A (xx) * 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a
AU5513298A (en) * 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
JP4261639B2 (ja) * 1998-08-05 2009-04-30 日本曹達株式会社 フェニルイミダゾール系抗高脂血症薬
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
WO2001077077A1 (en) * 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion

Also Published As

Publication number Publication date
RU2003112691A (ru) 2004-09-20
KR20030067675A (ko) 2003-08-14
BR0114657A (pt) 2003-09-30
NZ525591A (en) 2004-04-30
WO2002028835A1 (en) 2002-04-11
EP1326835A1 (en) 2003-07-16
JP2004510763A (ja) 2004-04-08
HUP0301249A2 (hu) 2004-01-28
CZ20031230A3 (cs) 2003-10-15
MXPA03003002A (es) 2004-12-06
PL362546A1 (en) 2004-11-02
NO20031540D0 (no) 2003-04-04
US20040058903A1 (en) 2004-03-25
CN1478077A (zh) 2004-02-25
CA2425097A1 (en) 2002-04-11
IL155196A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
NO20031540L (no) Benzamidforbindelser som Apo-B-sekresjonsinhibitorer
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
ATE524441T1 (de) Vla-4-inhibitoren
DK1383731T3 (da) Biarylforbindelser som serinproteaseinhibitorer
NO20034045L (no) Metallproteinase-inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DK1460066T3 (da) Piperazinforbindelse som tachykinin-inhibitorer
NO20030135D0 (no) Piperidinforbindelser for bruk som CCR-3 inhibitorer
NO20031450D0 (no) Fumarsyrederivater som NF-kappa B inhibitorer
NO20033593D0 (no) Kinazoliner som MMP-13 inhibitorer
DK1140840T3 (da) omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20025811D0 (no) Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer
AR027983A1 (es) Novedosos compuestos
NO20021407L (no) Bifenylderivater anvendt som NHE-3-inhibitorer
IS6657A (is) Ný efnasambönd
AR028220A1 (es) Novedosos compuestos
NO20011654D0 (no) Benzamidderivater som trombininhibitorer
AR028399A1 (es) Nuevos compuestos
NO20032290L (no) Nye forbindelser for anvendelse som HIV-protease-inhibitorer
NO20010900D0 (no) Oksamider som IMPDH-inhibitorer
SE0004680D0 (sv) New compound

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application